Dr. Nandini Verma
The biggest challenges in treating TNBC are chemoresistance and metastasis. These two factors are mostly responsible for breast cancer related deaths. A better insight of how the cancer cell escapes chemotherapy-induced cell death is of utmost importance in improving the prognosis. Studies have shown that the therapy induced molecular reprogramming event that occurs during treatment alters the secretome profile of the tumor microenvironment which contributes to drug resistance. My goal is to identify the drivers of chemo-resistance by understanding the therapy induced secretome landscape of cancer cells, which may give a clue about the therapeutic strategies that may be employed in resensitizing the drug resistance cancer cells to cytotoxic therapy.